How is Vivaglobin® administered and for how long?
Vivaglobin® is the first and only FDA-approved subcutaneous immunoglobulin (SCIg), meaning that with physician approval, Vivaglobin® can be self-administered by patients through injection subcutaneously, or under the skin. Vivaglobin® is supplied as a sterile liquid designed to be injected subcutaneously, preferably in the abdomen, thighs, upper arms, and/or lateral hip. Vivaglobin® must not be injected into a blood vessel. In the clinical trial, all subjects who received Vivaglobin® had previously been treated with intravenous immune globulin (IVIg). The prescribing information for Vivaglobin® recommends that a patient start treatment with this product one week after receiving a regularly scheduled IVIg infusion.
